is qsymia a glp-1 Qsymia® Results In Adult Patients Across BMI Qsymia for Medical Weight Loss

ESG is a non-surgical, incisionless procedure that reduces stomach size using sutures

BMJ 372:n71 Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials

Large cardiovascular outcome trials, including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide), have demonstrated cardiovascular risk reduction with GLP-1 receptor agonists

Key Benefits of Tirzepatide: Substantial Weight Loss: Tirzepatide has demonstrated the ability to help patients lose up to 20% or more of their body weight, making it one of the most potent weight loss medications available

In a dosing ranging study, 472 individuals who are overweight without diabetes were randomised and 72% completed 26 weeks of treatment